UCB - Ebit

Aktienkurs
264.50
Täglich Wechseln
-3.30 -1.23%
Monatlich
4.59%
Jährlich
64.44%
Q2 Prognose
257.81




Ebit Veränderung Datum
Alcon AG USD 317M 17M 2025-12
Almirall EUR 30.23M 12.8M 2025-12
Amarin USD -2.26M 564K 2025-12
argenx SE USD 371.14M 21.17M 2025-12
AstraZeneca USD 2.97B 4.48B 2025-12
Bayer EUR 1.11B 1.51B 2025-12
Galapagos EUR 780.56M 822.23M 2025-12
Genmab DKK 260M 199M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
GRIFOLS EUR 352.11M 20.18M 2025-09
Hikma Pharmaceutical USD 348M 31M 2025-12
Lonza CHF 673M 54M 2025-06
Merck EUR 474M 738M 2025-12
Novartis USD 4.06B 530M 2025-12
Orion EUR 328.1M 207.1M 2025-12
Recordati EUR 278.23M 112.58M 2025-12
Roche Holding CHF 9.56B 2.1B 2025-12
Sanofi EUR 1.7B 2.17B 2025-12
UCB EUR 1.29B 571M 2025-12
Unibail Rodamco EUR 844.1M 102.4M 2025-12